1. Home
  2. JBHT vs UTHR Comparison

JBHT vs UTHR Comparison

Compare JBHT & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo J.B. Hunt Transport Services Inc.

JBHT

J.B. Hunt Transport Services Inc.

HOLD

Current Price

$223.48

Market Cap

19.5B

Sector

Industrials

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$481.41

Market Cap

20.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBHT
UTHR
Founded
1961
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.5B
20.4B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
JBHT
UTHR
Price
$223.48
$481.41
Analyst Decision
Buy
Buy
Analyst Count
21
12
Target Price
$198.33
$498.83
AVG Volume (30 Days)
1.3M
311.0K
Earning Date
01-15-2026
02-25-2026
Dividend Yield
0.81%
N/A
EPS Growth
10.07
16.08
EPS
6.12
26.38
Revenue
$11,999,096,000.00
$3,128,400,000.00
Revenue This Year
$5.27
$13.57
Revenue Next Year
$6.78
$5.72
P/E Ratio
$36.24
$17.96
Revenue Growth
N/A
13.50
52 Week Low
$122.79
$266.98
52 Week High
$234.82
$519.99

Technical Indicators

Market Signals
Indicator
JBHT
UTHR
Relative Strength Index (RSI) 60.20 53.09
Support Level $208.86 $464.44
Resistance Level $234.82 $489.50
Average True Range (ATR) 7.34 11.00
MACD -0.05 0.94
Stochastic Oscillator 67.49 71.14

Price Performance

Historical Comparison
JBHT
UTHR

About JBHT J.B. Hunt Transport Services Inc.

J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (48% of sales), dedicated trucking services that provide customer-specific fleet needs (27%), for-hire truckload (6%), heavy goods final-mile delivery (7%), and asset-light truck brokerage (12%).

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: